Quick Answer
Lexaria Bioscience Corp. reported Diluted EPS of $0.66 per share (loss) for fiscal year 2025.
Lexaria Bioscience Corp. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.66 | -40.4% |
| 2024 | -$0.47 | +53.5% |
| 2023 | -$1.01 | -2425.0% |
| 2011 | -$0.04 | +0.0% |
| 2010 | -$0.04 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| November 30, 2025 | -$0.07 | +56.2% | +66.7% |
| May 31, 2025 | -$0.21 | -61.5% | -40.0% |
| February 28, 2025 | -$0.15 | -150.0% | +6.3% |
| November 30, 2024 | -$0.16 | -23.1% | -23.1% |
| May 31, 2024 | -$0.13 | — | -116.7% |
| February 29, 2024 | -$0.06 | — | +53.8% |
| November 30, 2023 | -$0.13 | — | — |
| July 31, 2012 | $0.00 | +100.0% | +100.0% |
- Lexaria Bioscience Corp. showed a decrease of -40.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2010–2025 period, Lexaria Bioscience Corp.’s diluted eps has declined by 1550.0% (from $0.04 per share (loss) to $0.66 per share (loss)).
- The most recent figure is from Lexaria Bioscience Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on November 28, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: